BMS Reports EXCALIBER-RRMM Results for ZENBEXUS
PRINCETON, N.J. — September 26, 2026 Bristol Myers Squibb announced the first presentation of results from the pivotal Phase...
MRD
Advertisement
Adaptive Highlights MRD Testing in New Myeloma Cure Definition
SEATTLE — September 25, 2026 Adaptive Biotechnologies highlighted a new consensus definition of cure for multiple myeloma presented at...
IMUNON Advances IMNN-001 Phase 2 After Favorable Safety Review
LAWRENCEVILLE, N.J. — September 22, 2026 IMUNON announced that the Independent Data Monitoring Committee (IDMC) overseeing its Phase 2...
Natera Reports Largest Lung Cancer MRD Study for Signatera
AUSTIN, Texas — September 18, 2026 Natera announced new data from the IASLC 2026 World Conference on Lung Cancer...
Adaptive Highlights Updated NCCN MRD Guidance in Multiple Myeloma
SEATTLE, Wash. — September 17, 2026 Adaptive Biotechnologies highlighted updates to the National Comprehensive Cancer Network (NCCN) Guidelines for...
Advertisements
Cytek Biosciences Highlights Spectral Flow Cytometry at ESCCA
Fremont, California, USA — September 3, 2026 Cytek Biosciences, Inc. announced that it will showcase its spectral flow cytometry...
Natera Validates Signatera for Lymphoma MRD Assessment
AUSTIN, Texas, September 1, 2026 Natera announced publication of new clinical data in Blood Neoplasia supporting the prognostic and...
Natera Partners With Susan G. Komen to Advance Breast Cancer Awareness
Austin, Texas – August 28, 2026 Natera, Inc. announced a new national partnership with Susan G. Komen to accelerate...
IMUNON Highlights Phase 3 OVATION 3 Trial at R&D Day
Lawrenceville, New Jersey – August 26, 2026 IMUNON announced plans to host its 2026 R&D Day on September 23...
NeoGenomics Gains Medicare Coverage for RaDaR ST Monitoring
Fort Myers, Florida – August 26, 2026 NeoGenomics announced that its RaDaR ST molecular residual disease (MRD) assay has...
Advertisement
